Determinants of protracted cytomegalovirus infection in solid-organ transplant patients

Transplantation

Volumn 74, Issue 2, 2002, Pages 226-236

  Muheim, Carmen ^a   Vogel, Gerard ^a   Seydoux, Charles ^a   Gillet, Michel ^a   Mosimann, Francois ^a   Von Segesser, Ludwig ^a   Sahli, Roland ^a   Estrade, Christine ^a   Van Melle, Guy ^b   Meylan, Pascal R A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT INFECTION; RISK FACTOR; VIRUS LOAD;

EID: 0037183181     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200207270-00014     Document Type: Article

References (38)

1. Cytomegalovirus pneumonitis after cardiac transplantation
2. Cytomegalovirus disease in renal allograft recipients: A prospective study of the clinical features, risk factors and impact on renal transplantation
3. Cytomegalovirus infection and disease in renal transplant patients treated with cyclosporin
4. Cytomegalovirus infection following liver transplantation: Review of the literature
5. Cytomegalovirus
6. Cytomegalovirus prophylaxis in solid organ transplant recipients
7. Prevention of cytomegalovirus disease in transplant recipients
8. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia
9. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
10. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection
11. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
12. Highdose acyclovir compared with short-course preemptive ganciclovir therapy to preveat Cytomegalovirus disease in liver transplant recipients
13. Cytomegalovirus infection and disease in solid organ transplant recipients
14. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients
15. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
16. Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients
17. Valacyclovir for the prevention of cytomegalovims disease after renal transplantation
18. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis
19. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy
20. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients
21. Recurrent cytomegalovirus disease in solidorgan transplant recipients
22. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients
23. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients
24. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
25. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients
26. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants
27. Should recurrent cytomegalovirus infections in patients with liver transplantation be treated?
28. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: Relationship between compliance with the guidelines and prevention of CMV morbidity
29. Definitions of cytomegalovirus infection and disease
30. Single tube competitive PCR for quantitation of CMV DNA in the blood of HIV+ and solid organ transplant patients
31. Real time quantitative PCR
32. Molecular alterations in the aging immune system
33. Global epidemiology of tuberculosis
34. Postherpetic neuralgia: Pathogenesis, treatment, and prevention
35. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load
36. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
37. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
38. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: Effect of oral ganciclovir